Senior Lecturer, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaProject Manager, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaSenior Lecturer, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaRegulatory Affairs Associate (Primary Care), Merck, Sharp and Dohme Pty Ltd, Sydney, NSW, Australia.
Health Expect. 2014 Apr;17(2):154-63. doi: 10.1111/j.1369-7625.2011.00746.x. Epub 2012 Feb 1.
Allergic rhinitis is increasing globally despite treatment focussed on pharmacotherapy. This study aimed to (i) examine the range and proportion of symptoms and triggers experienced by patients with intermittent allergic rhinitis (IAR); (ii) conduct a qualitative analysis of strategies devised to control symptoms and triggers; and (iii) measure medication adherence.
A qualitative and observational study of data drawn from a randomized controlled trial on patients with IAR. Strategies collaboratively devised by participants and pharmacist staff to minimize symptoms and triggers were analysed thematically. In the 10-day observational study, the participants recorded all symptoms and triggers of IAR along with use of medications and these were analysed descriptively.
Number of 124 participants recorded 620 symptoms and identified 357 triggers of IAR. To minimize these, 579 strategies were devised in consultation with pharmacy staff. The frequency and type of strategy varied according to whether the goals were aimed at controlling symptoms or triggers. Adherence to a course of antihistamines over the 10-day trial was self-reported by participants with 36% indicating full adherence.
A large number and range of symptoms and triggers were identified, and individualized strategies were devised to minimize symptoms and triggers. Medication adherence was poor.
Patients with IAR can be assisted to identify their symptoms and triggers and develop relevant strategies to manage these. This approach has the potential to facilitate patient self-management of a chronic and incapacitating condition.
尽管治疗重点是药物治疗，但过敏性鼻炎在全球范围内仍呈上升趋势。本研究旨在：(i) 检查间歇性过敏性鼻炎（IAR）患者经历的症状和诱因的范围和比例；(ii) 对旨在控制症状和诱因的策略进行定性分析；以及 (iii) 测量药物依从性。
这是一项对 IAR 患者随机对照试验中数据进行的定性和观察研究。参与者和药剂师工作人员共同制定的旨在最小化症状和诱因的策略进行了主题分析。在为期 10 天的观察性研究中，参与者记录了所有 IAR 的症状和诱因，以及药物的使用情况，并进行了描述性分析。
124 名参与者共记录了 620 种症状，并确定了 357 种 IAR 诱因。为了最小化这些症状和诱因，与药剂师工作人员协商制定了 579 种策略。策略的频率和类型根据目标是控制症状还是诱因而有所不同。在为期 10 天的试验中，参与者自我报告了抗组胺药物的依从性，36%的参与者表示完全依从。
确定了大量和广泛的症状和诱因，并制定了个体化的策略来最小化症状和诱因。药物依从性差。
可以帮助 IAR 患者识别他们的症状和诱因，并制定相关策略来管理这些症状和诱因。这种方法有可能促进患者对慢性和使人丧失能力的疾病的自我管理。
